close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

26.75 +0.75 (+2.88%)
Streaming Delayed Price Updated: 3:36 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Why Celldex Therapeutics Shares Are Trading Higher Today
 
Via Benzinga
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Read How Cantor Views Celldex Therapeutics' Barzolvolimab Data
 
Via Benzinga
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study
 
Via Benzinga
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
Company to host webcast on Sunday, February 26 at 4:00 pm CT/5:00 pm ET 
From Celldex Therapeutics, Inc.
Via GlobeNewswire
These '20 Stocks To Watch' Moved On Last Fed Rate Hike: How Will They React Today?
The Federal Reserve's interest rate hike announcements have the potential to cause significant volatility in the stock market. 
Via Benzinga
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Topics Death
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing... 
Via TheNewswire.com
Topics Death
BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX< 
Via Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex to Participate in Upcoming November Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
Celldex Therapeutics (NASDAQ:CLDX) brought in sales totaling $163 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 56.2%, resulting in a loss of $36.00... 
Via Benzinga
Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday
Gainers Omeros Corporation (NASDAQ: OMER) jumped 68.7% to close at $4.64. Clovis Oncology, Inc. (NASDAQ: CLVS) gained 58.3% to settle at $2.85 on Friday. 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know
HC Wainwright & Co. has decided to maintain its Buy rating of Celldex Therapeutics (NASDAQ:CLDX) and raise its price target from $60.00 to $73.00. Shares of Celldex Therapeutics are trading down 14.91%... 
Via Benzinga
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
The study was in 26 patients with chronic hives that don't respond to antihistamines. 
Via Investor's Business Daily
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
77 Biggest Movers From Yesterday
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today